NKX2-5 and central nervous system cancer: Interestingly, when we analyzed its mRNA expression levels in the CGGA (Chinese Glioma Genome Atlas) cohort59 of primary (n = 651) and recurrent (n = 332) gliomas, we found that NKX2.5 is significantly more expressed in grade IV gliomas compared to both grade III and grade II, and this difference holds true not only in primary but also in recurrent tumors (Fig. 7B).